GlassScriptPhysician profile
Andrew D Rosner
NPI 1528370251
$1,328.89
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $177 · 2021: $457 · 2022: $209 · 2023: $38.94 · 2024: $58.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $212.10 | 2019-2022 | |
| Pfizer INC. | $205.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.17 | 2019-2023 | Jardiance |
| Abbvie INC. | $141.81 | 2021-2024 | |
| Glaxosmithkline, LLC. | $74.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $61.42 | 2019-2022 | |
| Lilly USA, LLC | $50.10 | 2019-2020 | |
| Allergan, INC. | $49.45 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.79 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.69 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.96 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $32.07 | 2020-2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $26.97 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.39 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.83 | 2022 | |
| Abbott Laboratories | $17.22 | 2021 | |
| Amgen INC. | $16.56 | 2019 | |
| Merck Sharp & Dohme LLC | $15.97 | 2021 | |
| Bausch Health US, LLC | $15.90 | 2022 | |
| Amarin Pharma, INC. | $15.35 | 2019 | |
| Gilead Sciences, INC. | $14.62 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.59 | 2021 | |
| Sanofi Pasteur INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rosner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.